465 related articles for article (PubMed ID: 24652987)
21. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C Virus-Induced Myeloid-Derived Suppressor Cells Suppress NK Cell IFN-γ Production by Altering Cellular Metabolism via Arginase-1.
Goh CC; Roggerson KM; Lee HC; Golden-Mason L; Rosen HR; Hahn YS
J Immunol; 2016 Mar; 196(5):2283-92. PubMed ID: 26826241
[TBL] [Abstract][Full Text] [Related]
23. IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential.
Lehmann D; Spanholtz J; Sturtzel C; Tordoir M; Schlechta B; Groenewegen D; Hofer E
PLoS One; 2014; 9(1):e87131. PubMed ID: 24498025
[TBL] [Abstract][Full Text] [Related]
24. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
[TBL] [Abstract][Full Text] [Related]
25. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
[TBL] [Abstract][Full Text] [Related]
26. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16.
Pörtner LM; Schönberg K; Hejazi M; Brünnert D; Neumann F; Galonska L; Reusch U; Little M; Haas R; Uhrberg M
Cancer Immunol Immunother; 2012 Oct; 61(10):1869-75. PubMed ID: 22976535
[TBL] [Abstract][Full Text] [Related]
27. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3.
Scott AA; Head DR; Kopecky KJ; Appelbaum FR; Theil KS; Grever MR; Chen IM; Whittaker MH; Griffith BB; Licht JD
Blood; 1994 Jul; 84(1):244-55. PubMed ID: 7517211
[TBL] [Abstract][Full Text] [Related]
28. Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice.
Khoshtinat Nikkhoi S; Yang G; Owji H; Grizotte-Lake M; Cohen RI; Gil Gonzalez L; Massumi M; Hatefi A
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38490714
[TBL] [Abstract][Full Text] [Related]
29. Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models.
Shime H; Kojima A; Maruyama A; Saito Y; Oshiumi H; Matsumoto M; Seya T
J Innate Immun; 2014; 6(3):293-305. PubMed ID: 24192491
[TBL] [Abstract][Full Text] [Related]
30. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors.
Marin V; Pizzitola I; Agostoni V; Attianese GM; Finney H; Lawson A; Pule M; Rousseau R; Biondi A; Biagi E
Haematologica; 2010 Dec; 95(12):2144-52. PubMed ID: 20713459
[TBL] [Abstract][Full Text] [Related]
31. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
[TBL] [Abstract][Full Text] [Related]
32. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
Chen J; Zhou JH; Ball ED
Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
[TBL] [Abstract][Full Text] [Related]
33. Bi/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy.
Bahrololoumi Shapourabadi M; Momburg F; Roohvand F; Jarahian M; Mohajel N; Arashkia A; Hajari Taheri F; Abbasalipour M; Azadmanesh K
Int Immunopharmacol; 2021 Jul; 96():107762. PubMed ID: 34162140
[TBL] [Abstract][Full Text] [Related]
34. Optimized quantification of lymphocyte subsets by use of CD7 and CD33.
Hauser A; Schrattbauer K; Najdanovic D; Schlossnickel R; Koch A; Hejtman M; Krugluger W
Cytometry A; 2013 Mar; 83(3):316-23. PubMed ID: 23315982
[TBL] [Abstract][Full Text] [Related]
35. Imlifidase Inhibits HLA Antibody-mediated NK Cell Activation and Antibody-dependent Cell-mediated Cytotoxicity (ADCC) In Vitro.
Ge S; Chu M; Choi J; Louie S; Vo A; Jordan SC; Toyoda M
Transplantation; 2020 Aug; 104(8):1574-1579. PubMed ID: 32732834
[TBL] [Abstract][Full Text] [Related]
36. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
[TBL] [Abstract][Full Text] [Related]
37. Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation.
Kuwahara A; Nagai K; Nakanishi T; Kumagai I; Asano R
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255436
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors.
Sahin U; Kraft-Bauer S; Ohnesorge S; Pfreundschuh M; Renner C
Cancer Immunol Immunother; 1996 Jan; 42(1):9-14. PubMed ID: 8625370
[TBL] [Abstract][Full Text] [Related]
39. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
Hoseini SS; Vadlamudi M; Espinosa-Cotton M; Tran H; Feng Y; Guo HF; Xu H; Cheung I; Cheung NV
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035113
[TBL] [Abstract][Full Text] [Related]
40. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome.
Carlsten M; Baumann BC; Simonsson M; Jädersten M; Forsblom AM; Hammarstedt C; Bryceson YT; Ljunggren HG; Hellström-Lindberg E; Malmberg KJ
Leukemia; 2010 Sep; 24(9):1607-16. PubMed ID: 20613786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]